FDA approves Ractigen Therapeutics’ RAG-01 IND for bladder cancer
RAG-01 is a new therapy aimed at treating non-muscle invasive bladder cancer (NMIBC). This regulatory milestone enables the commencement of clinical trials in the US. NMIBC accounts for